Merck & Co.’s PD1 blocker pembrolizumab is a force to be reckoned with. Already a US$15 billion per year antibody, it is on track to becoming industry’s top-selling product by 2023. Approved for treating more than 30 cancer types, it has transformed the oncology landscape. And for Dean Li, the latest president of Merck Research Laboratories, this creates a nice problem to have: how to build out the future of this franchise, without losing sight of other therapeutic opportunities?
Enjoying our latest content?
Log in or create an account to continue
- Access the most recent journalism from Nature's award-winning team
- Explore the latest features & opinion covering groundbreaking research
or
Interviewed by Asher Mullard
Questions and answers have been edited for length and clarity.
